NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
← Tirzepatide vendors

Shandong Aishi BiotechnologyTirzepatide

32 testslatest 5 Nov 2026$0.43/mg median
Peptide testing

Ordered Tirzepatide from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply
+2 more ↓
78%
Finnrick rating
#135 of 281 Tirzepatide vendors
25 of 32 classifiable tests passed
customers 4.7★ (20)
methodology · Purity focus
Finnrick analysis · Tirzepatide

A recent 91.2% purity result breaks a long recovery streak, after earlier sub-99.5% misses and a +56% fill outlier. Many passing tests lack batch IDs, so the evidence is mixed rather than a clean reliability profile.

methodology →
vendor intelligence report
Vendor Intelligence Report: Shandong Aishi Biotechnology

Corporate records tie Aishi to a real Dezhou entity, but registry data and storefront claims conflict over staff, licences and factory capacity. The report maps a dead canonical domain, replacement sales funnels, shared COAs and a near-name buyer-confusion risk.

32 pages8 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.07
94%
16
2
Tirzepatideselected
$0.43
78%
32
3
Retatrutide
$0.93
76%
26
4
Ipamorelin
$1.96
74%
4
5
BPC-157
-
56%
3
6
Tesamorelin
$2.10
47%
7
7
HGH
-
38%
3
8
Cagrilintide
$4.40
-
0
9
MOTS-c
-
-
0
10
Semaglutide
$0.65
-
0
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%6 Oct 2025: 73%29 Oct 2025: 70%4 Nov 2025: 71%5 Nov 2025: 72%25 Nov 2025: 73%5 Dec 2025: 75%6 Dec 2025: 76%29 Dec 2025: 77%15 Jan 2026: 79%15 Jan 2026: 80%26 Jan 2026: 82%2 Feb 2026: 77%2 Feb 2026: 73%2 Feb 2026: 70%4 Feb 2026: 71%15 Feb 2026: 73%18 Feb 2026: 73%20 Feb 2026: 74%20 Feb 2026: 75%20 Feb 2026: 72%26 Feb 2026: 73%3 Mar 2026: 74%6 Mar 2026: 75%6 Mar 2026: 76%6 Mar 2026: 77%2 Jun 2026: 78%16 Jun 2026: 79%17 Jun 2026: 79%26 Aug 2026: 80%14 Sep 2026: 80%23 Oct 2026: 81%5 Nov 2026: 78%15 Nov 2026: current 78%73%75%78%Oct 25Nov 26
Showing Tirzepatide tests only
Peptide testing

Ordered Tirzepatide from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply
Shandong Aishi Biotechnology Tirzepatide test history
COA-backed lab tests
1-10 of 32

About Shandong Aishi Biotechnology test results from Finnrick

Shandong Aishi Biotechnology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 91 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Shandong Aishi Biotechnology peptides in this dataset are BPC-157 (3 tests), GHK-Cu (16 tests) and HGH (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 91 recent tests.

Corrections
No corrections.
Peptide testing

Ordered Tirzepatide from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply